Senseonics partners with Beta Bionics to integrate Eversense 365 CGM with iLet bionic pancreas
Reuters2026/09/14 11:04- Senseonics entered a partnership with Beta Bionics to integrate the Eversense 365 CGM with the iLet Bionic Pancreas system.
- Integration targets an automated insulin delivery offering built around Eversense’s year-long implantable glucose sensor.
- Development work is expected to finish in Q4 2026.
- Commercial launch is planned for Q4 2026, subject to testing, validation, and regulatory requirements.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Historical data shows that a single rate hike is not enough to end a bull market; a full tightening cycle is the real threat.
Since 1945, the S&P 500 has experienced 12 bear markets with declines of over 20% and 4 deep corrections ranging from 18% to 20%. Among them, six occurred directly after interest rate hikes that triggered economic recessions, while two other cases had no relation to either rate hikes or recessions. Goldman Sachs believes that the market has already priced in multiple rate hike expectations; Morgan Stanley warns that rising yields could trigger a market correction; JPMorgan is more focused on oil prices and corporate earnings.
Rogers Communications Upgraded to Buy at Desjardins
Focus Graphite Establishes CA$2 Million Revolving Credit Facility With CIBC
Crypto prices
More
